Cuprina Holdings (Cayman) Ltd. engages in the manufacturing, sale, and supply of medical devices to manage and accelerate healing and closure of chronic wounds. The company employs 10 full-time employees The company went IPO on 2025-04-10. Its segments include Maggot Debridement Therapy Product (MDT) and Cosmeceutical Product. The company manufactures and distributes a line of medical grade sterile blowfly larvae bio-dressing products marketed under the MEDIFLY brand name, or the MEDIFLY products. The MEDIFLY products are used as a biological debridement tool for chronic wounds, in a procedure known as MDT, which is an effective alternative to surgical debridement. The company has two lines of chronic wound care products in its pipeline, such as Collagen dressings, including sponges, particles and hydrogels utilizing bullfrog collagen derived from the valorization of abattoir waste streams of American bullfrogs (Lithobates catesbeianus) and products utilizing medical leeches for wound treatment.
CUPR stock price ended at $5.74 on 星期三, after rising 45.69%
On the latest trading day Jun 24, 2026, the stock price of CUPR rose by 45.69%, climbing from $5.45 to $5.74. During the session, the stock saw a volatility of 43.27%, with prices oscillating between a daily low of $5.13 and a high of $7.35. Notably, trading volume dropped by 25.7M shares on the last day despite the price increase, which may signal a potential uptick in risk in the near term. A total of 25.8M shares were traded, equating to a market value of approximately $15.3M.